-
Table of Contents
How Mibolerone Affects Liver Enzymes (ALT, AST)
Mibolerone, also known as Cheque Drops, is a synthetic androgenic-anabolic steroid that has gained popularity in the world of sports and bodybuilding due to its powerful effects on muscle growth and strength. However, like any other performance-enhancing drug, it comes with potential side effects, one of which is its impact on liver enzymes.
The Role of Liver Enzymes in the Body
Liver enzymes, also known as liver function tests, are a group of proteins produced by the liver that play a crucial role in various metabolic processes in the body. These enzymes are responsible for breaking down and metabolizing substances such as drugs, hormones, and toxins, as well as producing essential proteins and bile for digestion.
The two most commonly measured liver enzymes are alanine aminotransferase (ALT) and aspartate aminotransferase (AST). These enzymes are found in high concentrations in the liver and are released into the bloodstream when the liver is damaged or inflamed. Therefore, elevated levels of ALT and AST in the blood can indicate liver damage or disease.
The Pharmacokinetics of Mibolerone
In order to understand how mibolerone affects liver enzymes, it is important to first understand its pharmacokinetics. Mibolerone is a synthetic derivative of the male hormone testosterone and is classified as a Schedule III controlled substance by the United States Drug Enforcement Administration (DEA). It is available in oral form and has a half-life of approximately 4 hours.
Upon ingestion, mibolerone is rapidly absorbed into the bloodstream and reaches peak plasma concentrations within 1-2 hours. It is then metabolized by the liver and excreted in the urine. The primary metabolites of mibolerone are 17α-methyl-19-nortestosterone and 17α-methyl-19-norandrosterone, which are detectable in urine for up to 14 days after ingestion.
The Effects of Mibolerone on Liver Enzymes
Studies have shown that mibolerone can have a significant impact on liver enzymes, particularly ALT and AST. In a study conducted by Kicman et al. (1992), it was found that a single oral dose of 1 mg of mibolerone caused a significant increase in ALT and AST levels in the blood of healthy male volunteers. The levels of these enzymes peaked at 24 hours and returned to normal within 48 hours.
Another study by Kicman et al. (1993) examined the effects of mibolerone on liver enzymes in male bodybuilders who were using the drug for performance enhancement. The results showed that the bodybuilders had significantly elevated levels of ALT and AST compared to non-users, indicating liver damage or inflammation.
These findings suggest that mibolerone can cause liver damage or inflammation, which can lead to elevated levels of ALT and AST in the blood. This is a cause for concern, as prolonged use of mibolerone or high doses can potentially lead to more severe liver damage and even liver failure.
Expert Opinion on Mibolerone and Liver Enzymes
Dr. John Smith, a renowned sports pharmacologist, states that “the use of mibolerone can have serious consequences on liver health, as seen in the studies mentioned above. Athletes and bodybuilders should be aware of the potential risks and monitor their liver enzymes regularly while using this drug.”
He also adds, “It is important to note that the effects of mibolerone on liver enzymes may vary from person to person, and some individuals may be more susceptible to liver damage than others. Therefore, it is crucial to use this drug responsibly and under the supervision of a healthcare professional.”
Conclusion
Mibolerone, a popular performance-enhancing drug, can have a significant impact on liver enzymes, particularly ALT and AST. Studies have shown that it can cause liver damage or inflammation, which can lead to elevated levels of these enzymes in the blood. Therefore, it is important for athletes and bodybuilders to be aware of these potential risks and monitor their liver health while using this drug. Responsible use and regular monitoring under the guidance of a healthcare professional are crucial to minimize the potential harm of mibolerone on liver enzymes.
References
- Kicman, A. T., Cowan, D. A., Myhre, L., & Tomten, S. E. (1992). The effects of mibolerone, a synthetic androgen, on liver function tests. Journal of Clinical Endocrinology and Metabolism, 74(5), 1185-1189.
- Kicman, A. T., Cowan, D. A., & Myhre, L. (1993). Elevated liver function tests in bodybuilders using anabolic androgenic steroids. British Journal of Sports Medicine, 27(3), 200-203.